Implementation of a blood irradiation program at a community cancer center

BACKGROUND: Blood component irradiation is an accepted method of preventing transfusion‐associated GVHD. Previous publications have largely focused on the technical aspects of the irradiation process itself, but relatively little attention has been paid to the details associated with the implementat...

Full description

Saved in:
Bibliographic Details
Published inTransfusion (Philadelphia, Pa.) Vol. 41; no. 12; pp. 1610 - 1616
Main Authors Patton, Gregory A., Skowronski, Michael G.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science Inc 01.12.2001
Blackwell Publishing
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:BACKGROUND: Blood component irradiation is an accepted method of preventing transfusion‐associated GVHD. Previous publications have largely focused on the technical aspects of the irradiation process itself, but relatively little attention has been paid to the details associated with the implementation of a blood irradiation program at the level of a community cancer center. STUDY DESIGN AND METHODS: An observational study was performed, detailing the specific operational, documentation, and quality assurance measures employed in providing a blood component‐irradiation service within the institutional context of a community cancer center. RESULTS: The Montgomery Cancer Center irradiated 589 units of blood components in 1998 and 1999 to provide a local blood bank with an alternative for procurement of irradiated blood components while complying with applicable quality assurance and regulatory requirements. CONCLUSION: Blood component irradiation is within the scope of most well‐equipped and adequately staffed community cancer centers. Establishment of a blood component irradiation program requires scrupulous physics and dosimetry support, both to ensure the quality of the irradiated component and to satisfy governmental agency regulatory requirements.
Bibliography:ark:/67375/WNG-3QNHBMJC-5
ArticleID:TRF41121610
istex:1BF88F760AA45C9CC08B43DB1F91360E841E3E30
Gregory A. Patton, MD, Northwest Cancer Specialists, PC, 265 North Broadway, Portland, OR 97227‐1800; e‐mail
gregory.patton@usoncology.com
Address reprint requests to
.
ISSN:0041-1132
1537-2995
DOI:10.1046/j.1537-2995.2001.41121610.x